Sex hormones in the cardiovascular system

Hormone Molecular Biology and Clinical Investigation

Volumn 18, Issue 2, 2014, Pages 89-103

  Dos Santos, Roger Lyrio ^a   Da Silva, Fabrício Bragança ^a   Ribeiro Jr , Rogério Faustino ^a   Stefanon, Ivanita ^a  

^a FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

Author keywords

Cardioprotection; Sex hormones; Vascular and cardiac function

Indexed keywords

ANGIOTENSIN RECEPTOR; CHOLESTEROL; ENDOTHELIN 1; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROGESTERONE; PROSTACYCLIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE; TAMOXIFEN; TESTOSTERONE;

CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DEPRESSED BLOOD PRESSURE; DYSLIPIDEMIA; ENDOMETRIOSIS; ENDOMETRIUM CANCER; ESTROGEN THERAPY; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; VENOUS THROMBOEMBOLISM; ANIMAL; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; METABOLISM; PATHOPHYSIOLOGY; SEX DIFFERENCE;

ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; ESTROGENS; GONADAL STEROID HORMONES; HORMONE REPLACEMENT THERAPY; HUMANS; PROGESTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SEX FACTORS;

EID: 84924404185     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/hmbci-2013-0048     Document Type: Review

References (136)

1. The ESHRE Capri Workshop Group. Hormones and cardiovascular health in women. Hum Reprod Update 2006;12: 483-97.
2. Mosca L, Manson JE, Sutherland SE, Langer RD, Manolio T, Barrett-Connor E. Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Circulation 1997;96:2468-82.
3. Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, Lolor RJ, Ganiats TG, Gomes AS, Gornik HL, Gracia C, Gulati M, Haan CK, Judelson DR, Keenan N, Kelepouris E, Michos ED, Newby LK, Oparil S, Ouyang P, Oz MC, Petitti D, Pinn VW, Redberg RF, Scott R, Sherif K, Smith SC Jr, Sopko G, Steinhorn RH, Stone NJ, Taubert KA, Todd BA, Urbina E, Wenger NK, Expert Panel/Writing Group, American Academy of Physician Assistants, American Association for Clinical Chemistry, American Association of Cardiovascular and Pulmonary Rehabilitation, American College of Chest Physicians, American College of Emergency Physicians, American Diabetes Association, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Echocardiography, American Society of Nuclear Cardiology, Association of Women's Health, Obstetric and Neonatal Nurses, Global Alliance for Women's Health, Mended Hearts, Inc, National Black Nurses Association, National Black Women's Health Imperative, National Women's Health Resource Center, North American Menopause Society, Partnership for Gender-Specific Medicine at Columbia University, Preventive Cardiovascular Nurses Association, Society for Vascular Medicine and Biology, Society for Women's Health Research, Society of Geriatric Cardiology, Women in Thoracic Surgery, WomenHeart: the National Coalition for Women with Heart Disease. Evidencebased guidelines for cardiovascular disease prevention in women: 2007 update. JACC 2007;49:1230-50.
4. Kuroski de Bold ML. Estrogen, natriuretic peptides and the renin-angiotensin system. Cardiovasc Res 1999;41:524-31.
5. Qiao X, McConnell KR, Khalil RA. Sex steroids and vascular responses in hypertension and aging. Gend Med 2008;5:S46-64.
6. Wang L, Szklo M, Folsom AR, Cook NR, Gapstur SM, Ouyang P. Endogenous sex hormones, blood pressure change, and risk of hypertension in postmenopausal women: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2012;224:228-34.
7. Miller VM. Sex based differences in vascular function. Women's Health 2010;6:737-52.
8. Maric-Bilkan C, Manigrasso MB. Differences in hypertension: contribution of the renin-angiotensin system. Gend Med 2012;9:287-91.
9. Jones TH. Testosterone deficiency: a risk factor for cardiovascular disease? Trends Endocrinol Metab 2010;21:496-503.
10. Nettleship JE, Jones RD, Channer KS, Jones TH. Testosterone and coronary artery disease. Front Horm Res 2009;37:91-107.
11. Traish AM, Guay A, Feeley R, Saad F. The dark side of testosterone deficiency: metabolic syndrome and erectile dysfunction. J Androl 2009;30:10-22.
12. Orshal JM, Khalil RA. Gender, sex hormones, and vascular tone. Am J Physiol Regul Integr Comp Physiol 2004;286:R233-49.
13. Cutini PH, Campelo AE, Agriello E, Sandoval MJ, Rauschemberger MB, Massheimer VL. The role of sex steroids on cellular events involved in vascular disease. J Steroid Biochem Mol Biol 2012;132:322-30.
14. Zhu Y, Bian Z, Lu P, Karas RH, Bao L, Cox D, Hodgin J, Shaul PW, Thoren P, Smithies O, Gustafsson JA, Mendelshon ME. Abnormal vascular function and hypertension in mice deficient in estrogen receptor ǎ. Science 2002;295:505-8.
15. Barton M, Meyer MR, Prossnitz ER. Estrogen-independent activation of estrogen receptors. Hypertension 2011;57:1056-7.
16. Knowlton AA, Lee AR. Estrogen and the cardiovascular system. Pharmacol Ther 2012;135:54-70.
17. Dessy C, Feron O, Balligand JL. The regulation of endothelial nitric oxide synthase by caveolin: a paradigm validated in vivo and share by the 'endothelium-derived hyperpolarizing factor'. Pflügers Arch Eur J Physiol 2010;459:817-27.
18. Fleming I. Molecular mechanisms underlying the activation of eNOS. Pflügers Arch Eur J Physiol 2010;459:793-806.
19. Takahashi K, Ohmichi M, Yoshida M, Hisamoto K, Mabuchi S, Arimoto-Ishida E, Mori A, Tsutsumi S, Tasaka K, Murata Y, Kurachi H. Both estrogen and raloxifene cause G1 arrest of vascular smooth muscle cells. J Endocrinol 2003;178:319-29.
20. Pare G, Krust A, Karas RH, Dupont S, Aronovitz M, Chambon P, Mendelsohn ME. Estrogen receptor-á mediates the protective effects of estrogen against vascular injury. Circ Res 2002;290:1087-92.
21. Fliegner D, Schubert C, Penkalla A, Witt H, Kararigas G, Dworatzek E, Staub E, Martus P, Ruiz Noppinger P, Kintscher U, Gustafsson JA, Regitz-Zagrosek V. Female sex and estrogen receptor-ǎ attenuate cardiac remodeling and apoptosis in pressure overload. Am J Physiol Regul Integr Comp Physiol 2010;298:1597-606.
22. Pedram A, Razandi M, O'Mahony F, Lubahn D, Levin ER. Estrogen receptor-beta prevents cardiac fibrosis. Mol Endocrinol 2010;24:2152-65.
23. Takada Y, Kato C, Kondo S, Korenaga R, Ando J. Cloning of cDNAs encoding G protein-coupled receptor expressed in human endothelial cells exposed to fluid shear stress. Biochem Biophys Res Commun 1997;240:737-41.
24. Yu X, Handong M, Barman SA, Liu AT, Sellers M, Stallone JN, Prossnitz ER, White RE, Han G. Activation of G protein-coupled estrogen receptor induces endothelium-independent relaxation of coronary artery smooth muscle. Am J Physiol Endocrinol Metab 2011;301:E882-8.
25. Kang L, Zhang X, Xie Y, Tu Y, Wang D, Liu Z, Wang ZY. Involvement of estrogen receptor variant ER-á36, Not GPR30, in nongenomic signaling. Mol Endocrinol 2010;24:709-21.
26. Meyer MR, Prossnitz ER, Barton M. The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function. Vascul Pharmacol 2011;55:17-25.
27. Schreiber SN, Knutti D, Brogli K, Uhlmann T, Kralli A. The transcriptional coactivator PGC-1 regulates the expression and activity of the orphan nuclear receptor ERRá. J Biol Chem 2003;278:9013-8.
28. Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 2006;125:789-99.
29. Giguère V. Transcriptional control of energy homeostasis by the estrogen-related receptors. Endocr Rev 2008;124:789-99.
30. Hamilton KL, Lin L, Wang Y, Knowlton AA. Effect of ovariectomy on cardiac gene expression: inflammation and changes in SOCS genes expression. Physiol Genomics 2007;32:254-63.
31. Santos RL, Marin EB, Gonçalves WL, Bissoli NS, Abreu GR, Moyses MR. Sex differences in the coronary vasodilation induced by 17 ǎ-oestradiol in the isolated perfused heart from spontaneously hypertensive rats. Acta Physiol 2010;200:203-10.
32. Kim KH, Bender JR. Membrane-initiated actions of estrogen on the endothelium. Moll Cell Endocrinol2009;308:3-8.
33. Wu Q, Chambliss KL, Umetani M, Mineo C, Shaul PW. Nonnuclear estrogen receptor signaling in the endothelium. J Biol Chem 2011;286:14737-43.
34. Haynes MP, Sinha D, Russell KS, Collinge M, Fulton D, Morales-Ruiz M, Sessa WC, Bender JR. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-A-ět pathway in human endothelial cells. Circ Res 2000;87:677-82.
35. Mendelsohn ME. Genomic and nongenomic effects of estrogen in the vasculature. Am J Cardiol 2002;90:3F-6F.
36. Lantin-Hermoso RL, Rosenfeld CR, Yuhama IS, German Z, Chen Z, Shaul PW. Estrogen acutely stimulates nitric oxide synthase activity in fetal pulmonary artery endothelium. Am J Physiol 1997;273:L119-26.
37. Caulin-Glaser T, Garcia-Cardeña G, Sarrel P, Sessa WC, Bender JR. 17 beta-estradiol regulation of human endothelial cell basal nitric oxide release, independent of cytosolic Ca2+ mobilization. Circ Res 1997;81:885-92.
38. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW. Estrogen receptor á mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 1999;103:401-6.
39. Chambliss KL, Yuhanna IS, Anderson RG, Mendelsohn ME, Shaul PW. ERbeta has nongenomic action in caveolae. Mol Endocrinol 2002;16:938-46.
40. Prossnitz ER, Arterburn JB, Sklar LA. GPR30: a G protein-coupled receptor for estrogen. Moll Cell Endocrinol 2007;265-6:138-42.
41. Scarpin KM, Graham JD, Mote PA, Clarke CL. Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression. NURSA 2009;7:1-13.
42. Conneely OM, Mulac-Jericevic B, DeMayo F, Lydon JP, O'Malley BM. Reproductive Functions of Progesterone Receptors. Recent Prog Horm Res 2002;57:339-55.
43. Leonhardt SA, Boonyaratanakornkit V, Edwards DP. Progesterone receptor transcription and non-transcription signaling mechanisms. Steroids 2003;68:761-70.
44. Zhu Y, Bond J, Thomas P. Identification, classification, and partial characterization of genes in humans and other vertebrates homologous to a fish membrane progestin receptor. Proc Natl Acad Sci USA 2003;100:2237-42.
45. Karteris E, Zervou S, Pang Y, Dong J, Hillhouse EW, Randeva HS, Thomas P. Progesterone signaling in human myometrium through two novel membrane G protein-coupled receptors: potential role in functional progesterone withdrawal at term. Mol Endocrinol 2006;20:1519-34.
46. Zhu Y, Rice CD, Pang Y, Pace M, Thomas P. Cloning, expression, and characterization of a membrane progestin receptor and evidence it is an intermediary in meiotic maturation of fish oocytes. Proc Natl Acad Sci USA 2003;100:2231-6.
47. Thomas P, Pang Y, Dong J, Groenen P, Kelder J, de Vlieg J, Zhu Y, Tubbs C. Steroid and G protein binding characteristics of the seatrout and human progestin membrane receptor alpha subtypes and their evolutionary origins. Endocrinology 2007;148:705-18.
48. Wilson CM, McPhaul MJ. á and ǎ forms of the androgen receptor are expressed in a variety of human tissues. Mol Cell Endocrinol 1996;120:51-7.
49. Negro-Vilar A. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab 1999;84:3459-62.
50. Bhasin S, Jasuja R. Selective androgen receptor modulators as function promoting therapies. Curr Opin Clin Nutr Metab Care 2009;12:232-40.
51. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension 2001;37:1199-208.
52. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S. Adverse events associated with testosterone administration. N Engl J Med 2010;363:109-22.
53. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011;96:3007-19.
54. Ohlsson C, Barrett-Connor E, Bhasin S, Orwoll E, Labrie F, Karlsson MK, Ljunggren O, Vandenput L, Mellström D, Tivesten A. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am Coll Cardiol 2011;58:1674-81.
55. Carson CC III, Rosano G. Exogenous testosterone, cardiovascular events, and cardiovascular risk factors in elderly men: a review of trial data. J Sex Med 2012;9:54-67.
56. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 2000;102:1906-11.
57. Brockenbrough AT, Dittrich MO, Page ST, Smith T, Stivelman JC, Bremner WJ. Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease. Am J Kidney Dis 2006;47:251-62.
58. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, Morales AM, Volterrani M, Yellowlees A, Howell JD, Channer KS, TIMES2 Investigators. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011;34:828-37.
59. Grohé C, Kahlert S, Löbbert K, Stimpel M, Karas RH, Vetter H, Neyses L. Cardiac myocytes and fibroblasts contain functional estrogen receptors. FEBS Lett 1997;13:107-12.
60. Grohé C, Kahlert S, Löbbert K, Vetter H. Expression of oestrogen receptor alpha and beta in rat heart: role of local oestrogen synthesis. J Endocrinol 1998;156:R1-7.
61. Chu SH, Goldspink P, Kowalski J, Beck J, Schwertz DW. Effect of estrogen on calcium-handling proteins, beta-adrenergic receptors, and function in rat heart. Life Sci 2006;79:1257-67.
62. Thawornkaiwong A, Preawnim S, Wattanapermpool J. Upregulation of beta 1-adrenergic receptors in ovariectomized rat hearts. Life Sci 2003;72:1813-24.
63. Johnson BD, Zheng W, Korach KS, Scheuer T, Catterall WA, Rubanyi GM. Increased expression of the cardiac L-type calcium channel in estrogen receptor-deficient mice. J Gen Physiol 1997;110:135-40.
64. Bupha-Intr T, Wattanapermpool J. Regulatory role of ovarian sex hormones in calcium uptake activity of cardiac sarcoplasmic reticulum. Am J Physiol 2006;291:H1101-8.
65. Wattanapermpool J. Increase in calcium responsiveness of cardiac myofilament activation in ovariectomizedrats. Life Sci 1998;63:955-64.
66. Jiang C, Poole-Wilson PA, Sarrel PM, Mochizuki S, Collins P, MacLeod KT. Effect of 17 beta-oestradiol on contraction, Ca2+ current and intracellular free Ca2+ in guinea-pig isolated cardiac myocytes. Br J Pharmacol 1992;106:739-45.
67. Kilic A, Javadov S, Karmazyn M. Estrogen exerts concentrationdependent pro-and anti-hyperthophic effects on adult cultured ventricular myocytes. Role of NHE-1 in estrogen-induced hyperthophy. J Mol Cell Cardiol 2009;46:360-9.
68. Alecrin IN, Aldrighi JM, Caldas MA, Gebara OC, Lopes NH, Ramires JA. Acute and chronic effects of oestradiol on left ventricular diastolic function in hypertensive postmenopausal women with left ventricular diastolic dysfunction. Heart 2004;90:777-81.
69. Schaible TF, Malhotra A, Ciambrone G, Scheuer J. The effects of gonadectomy on left ventricular function and cardiac contractile proteins in male and female rats. Circ Res 1984;54:38-49.
70. Scheuer J, Malhotra A, Schaible TF, Capasso J. Effects of gonadectomy and hormonal replacement on rat hearts. Circ Res 1987;61:12-9.
71. Ren J, Hintz KK, Roughead ZK, Duan J, Colligan PB, Ren BH, Lee KJ, Zeng H. Impact of estrogen replacement on ventricular myocyte contractile function and protein kinase B/Akt activation. Am J Physiol 2003;284:H1800-7.
72. Kravtsov GM, Kam KW, Liu J, Wu S, Wong TM. Altered Ca2+ handling by ryanodine receptor and Na+-Ca2+ Exchange in the heart from ovariectomized rats: role of protein kinase A. Am J Physiol 2007;292:1625-35.
73. Paigel AS, Ribeiro RF Jr, Fernandes AA, Targueta GP, Vassallo DV, Stefanon I. Myocardial contractility is preserved early but reduced late after ovariectomy in young female rats. Reprod Biol Endocrinol 2011;23:9:54.
74. Koss KL, Kranias EG. Phospholamban: a prominent regulator of myocardial contractility. Circ Res 1996;79:1059-63.
75. Kadambi VJ, Ponniah S, Harrer J, Hoit B, Dorn GW, Walsh RA, Kranias EG. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J Clin Invest 1996;97:533-9.
76. Kiss E, Jakab G, Kranias EG, Edes I. Thyroid hormone-induced alterations in phospholamban protein expression. Regulatory effects on sarcoplasmic reticulum Ca2+ transport and myocardial relaxation. Circ Res1994;75:245-51.
77. Proudler AJ, Ahmed AI, Crook D, Fogelman I, Rymer JM, Stevenson JC. Hormone replacement therapy and serum angiotensinconverting-enzyme activity in postmenopausal women. Lancet 1995;346:89-90.
78. Fischer M, Baessler A, Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res 2002;53:672-7.
79. Gallagher PE, Li P, Lenhart JR, Chappell MC, Brosnihan KB. Estrogen regulation of angiotensin-converting enzyme mRNA. Hypertension 1999;33:323-8.
80. Serneri GG, Boddi M, Cecioni I, Vanni S, Coppo M, Papa ML, Bandinelli B, Bertolozzi I, Polidori G, Toscano T, Maccherini M, Modesti PA. Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Circ Res 2001;88:961-8.
81. De Mello WC. Novel aspects of angiotensin II action in the heart. Implications to myocardial ischemia and heart failure. Regul Pept 2011;166:9-14.
82. Ribeiro RF Jr, Pavan BM, Potratz FF, Fiorim J, Simoes MR, Dias FM, Lima FL, Fernandes AA, Vassallo DV, Stefanon I. Myocardial contractile dysfunction induced by ovariectomy requires AT1 receptor activation in female rats. Cell Physiol Biochem 2012;30:1-12.
83. Kimura N, Mizokami A, Oonuma T, Sasano H, Nagura H. Immunocytochemical localization of androgen receptor with polyclonal antibody in paraffin-embedded human tissues. J Histochem Cytochem 1993;41:671-8.
84. Nahrendorf M, Frantz S, Hu K, von zurMühlen C, Tomaszewski M, Scheuermann H, Kaiser R, Jazbutyte V, Beer S, Bauer W, Neubauer S, Ertl G, Allolio B, Callies F. Effect of testosterone on post-myocardial infarction remodeling and function. Cardiovasc Res 200;357:370-8.
85. Frantz S, Hu K, Widder J, Weckler B, Scheuermann H, Bauersachs J, Ertl G, Callies F, Allolio B. Detrimental effects of testosterone on post-myocardial infarction remodelling in female rats. J Physiol Pharmacol 2007;58:717-72.
86. Chen Y, Fu L, Han Y, Teng Y, Sun J, Xie R, Cao J. Testosterone replacement therapy promotes angiogenesis after acute myocardial infarction by enhancing expression of cytokines HIF-1a, SDF-1a and VEGF. Eur J Pharmacol 2012;684:116-24.
87. Kang NN, Fu L, Xu J, Han Y, Cao JX, Sun JF, Zheng M. Testosterone improves cardiac function and alters angiotensin II receptors in isoproterenol-induced heart failure. Arch Cardiovasc Dis 2012;105:68-76.
88. Rosano GM, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E, della Monica PL, Bonfigli B, Volpe M, Chierchia SL. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 1999;99:1666-70.
89. Subbiah MT, Abplanalp W. Evidence of increased formation of products retaining strong antioxidant activity from estradiol-17beta oxidation in the presence of human plasma lipoproteins. J Lab Clin Med 2002;139:357-63.
90. Salt PJ. Inhibition of noradrenaline uptake2 in the isolated rat heart by steroids, clonidine and methoxylatephenethylamines. Eur J Pharmacol 1972;20:329-40.
91. Haynes MP, Li L, Sinha D, Russell KS, Hisamoto K, Baron R, Collinge M, Sessa WC, Bender JR. Src kinase mediates phosphatidylinositol 3-kinase/Aktdependent rapid endothelial nitric-oxide synthase activation by estrogen. J Biol Chem 2003;278:2118-23.
92. Santos RL, Abreu GR, Bissoli NS, Moysés MR. Endothelial mediators of 17ǎ-estradiol-induced coronary vasodilation in the isolated rat heart. Braz J Med Biol Res 2004;37:569-75.
93. Jiang C, Sarrel PM, Lindsay DC, Poole-Wilson PA, Collins P. Endothelium-independent relaxation of rabbit coronary artery by 17ǎ-oestradiol in vitro. Br J Pharmacol 1991;104:1033-7.
94. Collins P, Rosano GM, Jiang C, Lindsay D, Sarrel PM, Poole-Wilson PA. Cardiovascular protection by oestrogen -a calcium antagonist effect? Lancet 1993;341:1264-5.
95. Valverde MA, Rojas P, Amigo J, Cosmelli D, Patricio O, Bahamonde MI, Mann GE, Vergara C, Latorre R. Acute activation of maxi-K channels (hSlo) by estradiol binding to the ǎ subunit. Science 1999;285:1929-31.
96. Tsang SY, Yao X, Chan HY, Wong CM, Chen ZY, Au CL, Huang Y. Contribution of K+ channels to relaxation induced by 17betaestradiol but not by progesterone in isolated rat mesenteric artery rings. J Cardiovasc Pharmacol 2003;41:4-13.
97. Dubey RK, Jackson EK. Estrogen-induced cardio renal protection: potential cellular, biochemical, and molecular mechanisms. Am J Physiol Renal Physiol 2001;280:F365-88.
98. Brosnihan KB, Li P, Figueroa JP, Ganten D, Ferrario CM. Estrogen, nitric oxide, and hypertension differentially modulate agonist-induced contractile responses in female transgenic (mRen2)27 hypertensive rats. Am J Physiol Heart Circ Physiol 2008;294:H1995-2001.
99. Selles J, Polini N, Alvarez C, Massheimer V. Progesterone and 17 ǎ-estradiol acutely stimulate nitric oxide synthase activity in rat aorta and inhibit platelet aggregation Life Sci 2001;69:815-27.
100. Crews JK, Khalil RA. Antagonistic effects of 17 ǎ-estradiol, progesterone, and testosterone on Ca2+ entry mechanisms of coronary vasoconstriction. Arterioscler Thromb Vasc Biol 1999;19:1034-40.
101. Wassmann K, Wassmann S, Nickenig G. Progesterone antagonizes the vasoprotective of estrogen on antioxidant enzyme expression and function. Circ Res 2005;97:1046-54.
102. Smiley DA, Khalil RA. Estrogenic compounds, estrogen Rreceptors and vascular cell signaling in the aging blood vessels. Curr Med Chem 2009;16:1863-87.
103. Simoncini T, Mannella P, Fornari L, Caruso A, Willis MY, Garibalde S, Baldacci C, Genazzani AR. Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology 2004;145:5745-56.
104. Perusquía M, Navarrete E, Gonzalez L, Villalón CM. The modulatory role of androgens and progestins in the induction of vasorelaxation in human umbilical artery. Life Sci 2007;81:993-1002.
105. Rowell KO, Hall J, Pugh PJ, Jones TH, Channer KS, Jones RD. Testosterone acts as an efficacious vasodilator in isolated human pulmonary arteries and veins: evidence for a biphasic effect at physiological and supra-physiological concentrations. J Endocrinol Invest 2009;32:718-23.
106. Tep-areenan P, Kendall DA, Randall MD. Testosterone-induced vasorelaxation in the rat mesenteric arterial bed is mediated predominantly via potassium channels. Br J Pharmacol 2002;135:735-40.
107. Kelly DM, Jones TH. Testosterone: a vascular hormone in health and disease. J Endocrinol 2013;217:R47-71.
108. Jones RD, Pugh PJ, Jones TH, Channer KS. 1Endocrine. Thevasodilatory action of testosterone: a potassium-channel opening or a calcium antagonistic action? Br J Pharmacol 2003;138:733-44.
109. English KM, Jones RD, Jones TH, Morice AH, Channer KS. Testosterone acts as a coronary vasodilator by a calcium antagonistic action. J Endocrinol Invest 2002;25:455-8.
110. Hall J, Jones RD, Jones TH, Channer KS, Peers C. Selective inhibition of L-type Ca2 channels in A7r5 cells by physiological levels of testosterone. Endocrinology 2006;147:2675-80.
111. Cairraö E, Alvarez E, Santos-Silva AJ, Verde I. Potassium channels are involved in testosterone-induced vasorelaxation of human umbilical artery. NaunynSchmiedebergs Arch Pharmacol 2008;376:375-83.
112. Seyrek M, Yildiz O, Ulusoy HB, Yildirim V. Testosterone relaxes isolated human radial artery by potassium channel opening action. J Pharm Sci 2007;103:309-16.
113. Deenadayalu V, Puttabyatappa Y, Liu AT, Stallone JN, White RE. Testosterone-induced relaxation of coronary arteries: activation of BKCa channels via the cGMP-dependent protein kinase. Am J Physiol Heart Circ Physiol 2012;302:H115-23.
114. Montaño LM, Calixto E, Figueroa A, Flores-Soto E, Carbajal V, Perusquía M. Relaxation of androgens on rat thoracic aorta: testosterone concentration dependent agonist/antagonist L-type Ca2+ channel activity, and 5beta-dihydrotestosterone restricted to L-type Ca2+ channel blockade. Endocrinology 2008;149:2517-26.
115. Waldkirch E, Uckert S, Schultheiss D, Geismar U, Bruns C, Scheller F, Jonas U, Becker AJ, Stief CG, Hedlund P. Nongenomic effects of androgens on isolated human vascular and nonvascular penile erectile tissue. BJU Int 2008;101:71-5.
116. Bordallo J, Cantabrana B, Suárez L, Sánchez M. Testosterone inhibits cAMP-phosphodiesterases in heart extracts from rats and increases cAMP levels in isolated left atria. Pharmacology 2011;87:155-60.
117. Chou TM, Sudhir K, Hutchison SJ, Ko E, Amidon TM, Collins P, Chatterjee K. Testosterone induces dilation of canine coronary conductance and resistance arteries in vivo. Circulation 1996;94:2614-9.
118. Preston RA. Comparative effects of conventional vs. novel hormone replacement therapy on blood pressure in postmenopausal women. Climacteric 2009;12:66-70.
119. Gompel A, Boutouyrie P, Joannides R, Christin-Maitre S, Kearny-Schwartz A, Kunz K, Laurent S, Boivin JM, Pannier B, Pornel B, Thuillez C, Van Bortel L, Zannad F, Pithoois-Merli I, Jaillon P, Simon T. Association of menopause and hormone replacement therapy with large artery remodeling. Fertil Steril 2011;96:1445-50.
120. Yang XP, Reckelhoff JF. Estrogen, hormonal replacement therapy and cardiovascular disease. Hypertension 2011;20:133-8.
121. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabe, VM, Ko M, Lacroix AZ, Margolis KL, Stefanick ML. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. J Am Med Assoc 2007;297:1465-77.
122. Sare GM, Gray LJ, Philip MW. Bath PM. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J 2008;29:2031-41.
123. Franco V, Oparil S. Hormone replacement therapy and hypertension. Curr Opin Nephrol Hypertens 2002;11:229-35.
124. Xing D, Nozell S, Chen YF, Hage F, Oparil S. Estrogen and Mechanisms of Vascular Protection. Arterioscler Thromb Vasc Biol 2009;29:289-95.
125. Stice JP, Elserich JP, Knowlton AA. Role of aging versus the loss of estrogens in the reduction in vascular function in female rats. Endocrinology 2009;150:212-9.
126. LeBlanc AJ, Reyes R, Kang LS, Dailey RA, Stallone JN, Moningka NS, Muller-Delp JM. Estrogen replacement restores flow-induced vasodilation in coronary arterioles of aged and ovariectomized rats. Am J Physiol Regul Integr Comp Physiol 2009;297:1713-23.
127. Nilsson S, Koehler KF. Oestrogen receptors and selective oestrogen receptor modulators: molecular and cellular pharmacology. Basic Clin Pharmacol Toxicol 2005;96:15-25.
128. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609-18.
129. Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 1996;10:905-12.
130. Figtree GA, Lu Y, Webb CM, Collins P. Raloxifene acutely relaxes rabbit coronary arteries by an estrogen receptordependent and nitric oxide-dependent mechanism. Circulation 1999;100:1095-101.
131. Kim HP, Lee JY, Jeong JK, Bae SW, Lee HK, Jo I. Nongenomic stimulation of nitric oxide release by estrogen is mediated by estrogen receptor alpha localized in caveolae. Biochem Biophys Res Commun 1999;263:257-62.
132. Burger HG. Selective oestrogen receptor modulators. Horm Res 2000;53:25-9.
133. Borgo MV, Lopes AB, Gouvěa SA, Romero WG, Moyses MR, Bissoli NS, Abreu GR. Effect of tamoxifen on the coronary vascular reactivity of spontaneously hypertensive female rats. Braz J Med Biol Res 2011;44:786-92.
134. Couldwell WT, Weiss MH, DeGiorgio CM, Weiner LP, Hinton DR, Ehresmann GR, Conti PS, Apuzzo ML. Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 1993;32:485-9.
135. Arimidex, Tamoxifen, Alone or in Combination Trialists' Group, Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G, Houghton J, Locker GY, Nabholtz JM. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006;7:633-43.
136. Ek RO, Yildiz Y, Cecen S, Yenisey C, Kavak T. Effects of tamoxifen on myocardial ischemia-reperfusion injury model in ovariectomized rats. Mol Cell Biochem 2008;308:227-35.